Clinical Implications of Microsatellite Instability in T1 Colorectal Cancer

Jeonghyun Kang, Hak Woo Lee, Im-kyung Kim, Nam Kyu Kim, Seung-Kook Sohn, and Kang Young Lee
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.

Purpose: The estimation of regional lymph node metastasis (LNM) risk in T1 colorectal cancer is based on histologic examination and imaging of the primary tumor. High-frequency microsatellite instability (MSI-H) is likely to decrease the possibility of metastasis to either regional lymph nodes or distant organs in colorectal cancers. This study evaluated the clinical implications of MSI in T1 colorectal cancer with emphasis on the usefulness of MSI as a predictive factor for regional LNM.

Materials and Methods: A total of 133 patients who underwent radical resection for T1 colorectal cancer were included. Genomic DNA was extracted from normal and tumor tissues and amplified by polymerase chain reaction (PCR). Five microsatellite markers, BAT-25, BAT-26, D2S123, D5S346, and D17S250, were used. MSI and clinicopathological parameters were evaluated as potential predictors of LNM using univariate and multivariate analyses.

Results: Among 133 T1 colorectal cancer patients, MSI-H, low-frequency microsatellite instability (MSI-L), and microsatellite stable (MSS) colorectal cancers accounted for 7.5%, 6%, and 86.5%, respectively. MSI-H tumors showed a female predominance, a proximal location and more retrieved lymph nodes. Twenty-two patients (16.5%) had regional LNM. Lymphovascular invasion and depth of invasion were significantly associated with LNM. There was no LNM in 10 MSI-H patients; however, MSI status was not significantly correlated with LNM. Disease-free survival did not differ between patients with MSI-H and those with MSI-L/MSS.

Conclusion: MSI status could serve as a negative predictive factor in estimating LNM in T1 colorectal cancer, given that LNM was not detected in MSI-H patients. However, validation of our result in a different cohort is necessary.

Key Words: Microsatellite instability, lymph node metastasis, early colorectal cancer, T1, prognosis

INTRODUCTION

Although the basic principle in surgical management of colorectal cancer is wide resection of the primary tumor and adequate regional lymph node dissection, some modifications are appropriate in selected patients. When the cancer is confined to...
the mucosal layer, the tumor can be completely removed by an endoscopic procedure or local excision and further lymph node dissection is not necessary since there is no risk of lymph node metastasis (LNM) in these cancers. The same treatment strategy could be applied to invasive carcinoma if the risk of LNM could be predicted. However, the challenge in applying local resection to invasive carcinoma is predicting the presence of LNM. The risk of regional LNM increases in proportion to the depth of invasion. The overall LNM rate of T1 colorectal cancer was reported to range from 6% to 13%, which is relatively low compared to 19–28% for T2 and 36–65.4% for T3 and T4 cancer.\(^5,7\)

Currently, when a tumor is found to be confined within the submucosa during a preoperative workup, resection of the primary tumor is attempted. The possibility of LNM is subsequently evaluated based on histologic examination of the primary tumor with regard to features such as depth of invasion, presence of lymphovascular invasion, differentiation, and tumor budding.\(^4\) It is recommended that patients at high risk undergo radical resection due to the possibility of regional LNM. Given that the development of colorectal cancer is known to be the result of accumulating genetic alterations,\(^8\) it seems prudent to take into account histologic features of the primary tumor in addition to molecular biological characteristics for the prediction of regional LNM in T1 colorectal cancer. However, to the best of our knowledge, there are limited reports on predicting regional LNM in T1 colorectal cancer using molecular biological characteristics.\(^12\)

MSI is one of the prevalent carcinogenic pathways in colorectal cancer, caused by a mismatch repair gene defect resulting in loss or gain of tandem repeat sequences.\(^13-16\) A high frequency of microsatellite instability (MSI-H) has been found in most patients with hereditary nonpolyposis colorectal cancer (HNPCC), and occurs in approximately 15% of sporadic colorectal cancer cases.\(^15-18\) MSI-H tumors were associated with unique clinicopathological characteristics, such as younger age at onset, proximal location, and frequent peritumoral lymphocytic infiltration.\(^19-21\) Additionally, MSI-H tumors showed a lower incidence of LNM and a better survival rate.\(^21-24\) Most previous studies investigating the relationship between MSI and regional LNM were based on advanced colorectal cancers. However, little is known regarding the specific impact of MSI in early colorectal cancer.

Therefore, the aim of this study was to evaluate the clinical implications of MSI in T1 colorectal cancer with emphasis on the usefulness of MSI as a predictive factor for regional LNM.

### MATERIALS AND METHODS

#### Eligibility

Patients who underwent curative resection for T1 colon or rectal adenocarcinoma between January 2005 and May 2011 were selected from our prospectively collected database. Excluded from the initial selection were patients who had undergone preoperative chemotherapy or radiotherapy, patients who were diagnosed with HNPCC or a familial adenomatous polyposis, patients who underwent transanal excision, and patients initially diagnosed with stage IV disease. The inclusion of patients was based on the availability of MSI data, as well as a complete set of clinicopathological information including age, sex, tumor size, histologic grade, lymphovascular invasion, depth of invasion, date of surgery, location of the primary tumor, [proximal colon (cecal, ascending, or transverse colon), distal colon (descending, sigmoid, or rectosigmoid colon), or rectum], date of recurrence, pathologic nodal stage, and total retrieved lymph nodes. After exclusions, 133 patients were included in our analysis. This study was approved by our Institutional Review Board (number: 4-2010-0286).

#### Sectioning and microdissection

Genomic DNA was extracted from three to five sections of 10-μm-thick formalin-fixed, paraffin-embedded tissue blocks containing tumor and non-neoplastic mucosa using a QIAamp DNA mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Separate blocks were used for malignant and non-malignant tissue. Tumor blocks containing tumor and non-neoplastic mucosa were selected based on hematoxylin and eosin stained slides.

#### Microsatellite instability (MSI)

The MSI status of each tumor was determined with the following five markers: BAT 25, BAT 26, D2S123, D5S346, and D17S250. Fifty nanograms of DNA were amplified in a 20 μL reaction solution containing 2 μL of 10X buffer (Roche, Mannheim, Germany), 1.7 to 2.5 mmol/L of MgCl2, 0.3 μM of each primer pair, 250 μM of deoxynucleotide triphosphate, and 2.5 units of DNA polymerase (Roche). The primer sequences and polymerase chain reaction (PCR) cycles for each marker were adapted from the published data.\(^25\) Fluorescence markers (NED, FAM) were attached to the 5’
MSI was diagnosed when there were aberrant peaks or peak shifts compared to the normal control. A case was categorized as MSI-H if MSI was present at two or more markers, MSI-low (MSI-L) if only one of the five markers showed instability, and microsatellite stable (MSS) if no marker had evidence of MSI. In all of the analyses, MSI-L, and MSS tumors were grouped together and denoted as MSI-L/MSS.

Statistical analysis
All calculations and analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). The association of clinicopathological features with MSI status was analyzed using the two-sided Pearson’s chi-square test or Fisher’s exact test for categorical variables and Student’s t-test for continuous variables. Factors associated with LNM were analyzed by logistic regression with forward stepwise selection of variables. Disease-free survival (DFS) was defined as the time from the date of operation to the date of tumor recurrence or last follow-up. Survival analysis was performed with the Kaplan-Meier method. The log-rank test was used to compare survival outcome between groups. A $p$-value $<0.05$ was considered to indicate significance.

RESULTS

Patient characteristics
Patients’ characteristics are summarized in Table 1. The median age was 60 years (range: 32–84 years). The distribution of tumor locations was as follows: 29 in the proximal colon, 32 in the distal colon and 72 in the rectum. Twenty-two patients (16.5%) had regional LNM. Histologic grade examination revealed only one patient (0.8%) with poorly differentiated adenocarcinoma. The distribution of invasion was 47 sm1, 35 sm2, and 51 sm3. Lymphovascular invasion was detected in 18 patients (13.5%). The median tumor size was 1.9 cm (range: 0.2–8.0 cm).

Clinical characteristics of patients with MSI
An evaluation of tumor MSI status revealed MSS in 115 patients (86.5%), MSI-L in 8 patients (6.0%) and MSI-H in 10 patients (7.5%). MSI-L and MSS tumors were grouped together and denoted as MSI-L/MSS. Comparisons of clinicopathological characteristics between the MSI-H and MSI-L/MSS groups are summarized in Table 2. There was a female predominance in the MSI-H group ($p=0.005$). The predominant location in the MSI-H group was the proximal colon ($p=0.001$). There was no significant difference between the two groups with regard to the depth of tumor invasion, histologic grade, presence of lymphovascular invasion, or tumor size. In contrast, the number of total retrieved lymph nodes was higher in the MSI-H group ($p=0.044$). The number of metastatic lymph nodes in the MSI-H group was significantly lower in comparison to the MSI-L/MSS group ($p<0.001$).
Factors associated with LNM

Histologic grade, lymphovascular invasion, and depth of invasion were significantly associated with LNM by univariate analysis. Multivariate analysis indicated that lymphovascular invasion [hazard ratio (HR), 17.2; 95% confidence interval (CI), 4.8–61.0; \( p < 0.001 \)] and depth of invasion (comparing sm1 to sm3: HR, 4.4; 95% CI, 1.1–16.9; \( p = 0.030 \)) were independent risk factors for LNM. MSI-H was not correlated with regional LNM by univariate analysis (\( p = 0.213 \), Fisher’s exact test). However, there was no LNM in the MSI-H group (Table 3).

Survival analysis

We compared disease-free survival between patients with MSI-H and those with MSI-L/MSS (Fig. 1). There was no significant difference in three-year DFS between the two groups (100% in the MSI-H group; 93.7% in the MSI-L/MSS group; \( p = 0.542 \) (Fig. 1).

Table 2. Comparison of Clinicopathological Characteristics between MSI-H Group and MSI-L and MSS Group

|                      | MSI-H group (%) | MSI-L and MSS group (%) | \( p \) value |
|----------------------|-----------------|--------------------------|--------------|
| Gender               |                 |                          |              |
| Male                 | 1 (10)          | 72 (58.5)                | 0.005*       |
| Female               | 9 (90)          | 51 (41.5)                |              |
| Age (yrs)            |                 |                          |              |
| Mean (SD)            | 59.3 (9.4)      | 59.9 (10.1)              | 0.841        |
| Preoperative CEA (ng/mL) |             |                          |              |
| Mean (SD)            | 1.5 (1.3)       | 1.7 (1.5)                | 0.815        |
| Tumor location       |                 |                          |              |
| Proximal colon       | 7 (70)          | 22 (17.9)                | 0.001*       |
| Distal colon         | 0 (0)           | 32 (26.0)                |              |
| Rectum               | 3 (30)          | 69 (56.1)                |              |
| Depth of invasion    |                 |                          |              |
| Sm1                  | 2 (20)          | 45 (36.6)                | 0.502*       |
| Sm2                  | 4 (40)          | 31 (25.2)                |              |
| Sm3                  | 4 (40)          | 47 (38.2)                |              |
| pN                   |                 |                          |              |
| N negative           | 10 (100)        | 101 (82.1)               | 0.213*       |
| N positive           | 0 (0)           | 22 (17.9)                |              |
| LN numbers           |                 |                          |              |
| <12                  | 1 (10)          | 47 (38.2)                | 0.094*       |
| ≥12                  | 9 (90)          | 76 (61.8)                |              |
| No. of metastatic LNs|                 |                          |              |
| Mean (SD)            | 0               | 0.3 (0.7)                | <0.001       |
| No. of retrieved LNs |                 |                          |              |
| Mean (SD)            | 24.9 (12.1)     | 16.1 (13.1)              | 0.044        |
| Histologic grade\(^1\) |               |                          |              |
| G1                   | 2 (20)          | 44 (35.8)                | 0.531*       |
| G2                   | 8 (80)          | 78 (63.4)                |              |
| G3                   | 0 (0)           | 1 (0.8)                  |              |
| LVI                  |                 |                          |              |
| Negative             | 9 (90)          | 106 (86.2)               | 1.0*         |
| Positive             | 1 (10)          | 17 (13.8)                |              |
| Tumor size (cm)      |                 |                          |              |
| <2.0                 | 9 (90)          | 82 (66.7)                | 0.169*       |
| ≥2.0                 | 1 (10)          | 41 (33.3)                |              |

CEA, carcinoembryonic antigen; LN, lymph node; LVI, lymphovascular invasion; SD, standard deviation; MSI-H, high-frequency microsatellite instability; MSI-L, low-frequency microsatellite instability; MSS, microsatellite stable.

*Fisher’s exact test.

\(^{1}\)Histologic grade: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated.
The major finding of this study was that MSI status could be used as a negative predictive marker in estimating LNM in T1 colorectal cancer given that there was no LNM in MSI-H patients.

The standard treatment for colorectal cancer is complete resection of the primary tumor with regional lymphadenectomy due to the potential risk of regional LNM. However, in T1 colorectal cancer, regional lymphadenectomy can be omitted without deterioration of oncologic outcomes for selected patients with little risk of regional LNM. The prediction of regional LNM was made based on preoperative imaging and histologic characteristics of the primary tumor such as depth of tumor invasion, tumor differentiation and lymphovascular invasion. In current practice, even after complete removal of the primary tumor, an additional radiocal resection is recommended for patients found to have high LNM risk upon histologic examination. However, a large-scale multicenter study found that the actual rate of LNM was only 14‒23% according to respective high risk factors. For this reason, a great deal of effort has gone into reducing potential over-treatment by precise prediction of LNM risk.

In this study, the role of MSI was investigated as one of the predictive factors for LNM in T1 colorectal cancer, since we feel that in the prediction of early metastasis, biological

| Table 3. Factors Associated with Lymph Node Metastasis in T1 Colorectal Carcinoma |
|---------------------------------|----------------|------------------|----------------|
|                                 | Univariate | Multivariate     |               |
|                                 | (%)        | p value           | HR (95% CI)   | p value |
| Gender                          |            |                  |               |
| Male                            | 10/73 (13.7)| 0.330            | N/A           |
| Female                          | 12/60 (20.0)|                  |               |
| Age (yrs)                       |            |                  |               |
| <60                             | 11/61 (18.0)| 0.670            | N/A           |
| ≥60                             | 11/72 (15.3)|                  |               |
| Tumor location                  |            |                  |               |
| Proximal colon                  | 3/29 (10.3)| 0.405*           | N/A           |
| Distal colon & rectum           | 19/104 (18.3)|                 |               |
| Preoperative CEA (ng/mL)        |            |                  |               |
| <5.0                            | 21/129 (16.3)| 0.519*          | N/A           |
| ≥5.0                            | 1/4 (25.0) |                  |               |
| Histologic grade††             |            |                  |               |
| G1                              | 3/46 (6.5) | 0.024            | N/S           | N/S     |
| G2 & G3                         | 19/87 (21.8)|                 |               |
| LVI                             |            |                  |               |
| Negative                        | 11/115 (9.6)| <0.001*          | 1             | <0.001  |
| Positive                        | 11/18 (61.1)|                 | 17.2 (4.8–61.0)|       |
| Tumor size (cm)                 |            |                  |               |
| <2.0                            | 17/91 (18.7)| 0.328            | N/A           |
| ≥2.0                            | 5/42 (11.9) |                  |               |
| Depth of invasion               |            |                  |               |
| Sm1                             | 4/47 (8.5) | 0.007            | 1             |        |
| Sm2                             | 3/35 (8.6) | 0.7 (0.1–4.1)    | 0.710         |        |
| Sm3                             | 15/51 (29.4)|                 | 4.4 (1.1–16.9)| 0.030   |
| Microsatellite status           |            |                  |               |
| MSI-H                           | 0 /10 (0)  | 0.213*           | N/A           |
| MSI-L & MSS                     | 22/123 (17.9)|                 |               |

CEA, carcinoembryonic antigen; LVI, lymphovascular invasion; N/A, not applicable; N/S: non significant; HR, hazard ratio; CI, confidence interval; MSI-H, high-frequency microsatellite instability; MSI-L, low-frequency microsatellite instability; MSS, microsatellite stable.

Factors with p value less than 0.2 in univariate analysis were entered into multivariate analysis.

*Fisher’s exact test.

†Histologic grade: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated.
colon cancer and not in stage II colon cancer, the association was not evident in stage III colorectal cancer in another series. It was reported that this discrepancy might have originated from different uses of panels in defining MSI-H, different incidences of MSI-H phenotype, and limited numbers of MSI-H cases. In our study, although the frequency of MSI-H was relatively low (7.5%), a higher lymph node harvest was observed in MSI-H tumors (p=0.044), confirming the positive correlation of MSI-H and retrieved lymph node numbers. In the sub-group analysis of stage I patients (n=111), there was still a trend toward increased total retrieved lymph nodes in MSI-H tumors (MSI-H: mean of 24.9; MSI-L/MSS: mean of 16; p=0.062; data not shown).

The incidence of regional LNM was 16.5% in the current study, higher than in previous reports (6.3% to 13%). This difference may be the result of patient selection bias in this study. Most of the included patients were candidates for radical surgery because of the presence of risk factors for regional LNM or technical factors such as incomplete resection or difficulty in complete resection of the primary tumor. These factors could have contributed to the relatively high incidence of regional LNM; however, the fact that all included patients underwent radical surgery is a unique aspect of this study. For this reason, the presence of cancer metastasis to regional lymph nodes was confirmed by pathological examination. It is also noteworthy that there was no regional LNM in patients with MSI-H, even among high-risk patients. In conclusion, given that there was no LNM in this study, higher than in previous reports (6.3% to 13%).

Characteristics should be taken into account in addition to conventional pathologic examination. MSI-H cancers are reported to have a decreased likelihood of metastases to either regional LNs or distant organs. Interestingly, regional LNM was not identified in patients with MSI-H T1 colorectal cancers in this study. Although not statistically significant, the prominent difference in LNM between the MSI-H group (0%) and MSI-L/MSS group (17.9%) indicate the possibility that the lack of an observed association between MSI status and LNM may have been the result of a type II error related to insufficient sample size. In the studied cohort, lymphovascular invasion, and depth of invasion were identified as independent risk factors for LNM by multivariate analysis, consistent with other reports. Although this study was not substantial enough to make definite conclusions, our results suggest that MSI has the potential to be used as a predictive factor for LNM in T1 colorectal cancer.

Colorectal cancers with MSI-H have distinct clinicopathological features. MSI-H cancers tend to be associated with a slight predominance in females, proximal tumor location, large tumor size, greater depth of tumor invasion, and poor histology. Our data also demonstrated that MSI-H T1 colorectal cancer showed a female predominance, proximal tumor location and more retrieved lymph nodes.

The total number of retrieved lymph nodes in colorectal cancer is known to be positively correlated with good prognosis. Many studies demonstrated an association between MSI-H status and higher total lymph node counts. However, there are discrepancies among some studies. While Belt, et al. reported that high lymph node retrieval was associated with MSI-H tumors especially in stage III colorectal cancer and not in stage II colon cancer, the association was not evident in stage III colorectal cancer in another series. It was reported that this discrepancy might have originated from different uses of panels in defining MSI-H, different incidences of MSI-H phenotype, and limited numbers of MSI-H cases. In our study, although the frequency of MSI-H was relatively low (7.5%), a higher lymph node harvest was observed in MSI-H tumors (p=0.044), confirming the positive correlation of MSI-H and retrieved lymph node numbers. In the sub-group analysis of stage I patients (n=111), there was still a trend toward increased total retrieved lymph nodes in MSI-H tumors (MSI-H: mean of 24.9; MSI-L/MSS: mean of 16; p=0.062; data not shown).

The incidence of regional LNM was 16.5% in the current study, higher than in previous reports (6.3% to 13%). This difference may be the result of patient selection bias in this study. Most of the included patients were candidates for radical surgery because of the presence of risk factors for regional LNM or technical factors such as incomplete resection or difficulty in complete resection of the primary tumor. These factors could have contributed to the relatively high incidence of regional LNM; however, the fact that all included patients underwent radical surgery is a unique aspect of this study. For this reason, the presence of cancer metastasis to regional lymph nodes was confirmed by pathological examination. It is also noteworthy that there was no regional LNM in patients with MSI-H, even among high-risk patients. In conclusion, given that there was no LNM in patients with MSI-H tumors, MSI status could serve as a negative predictive factor in estimating LNM in T1 colorectal cancer. Although this study showed the possibility of negative predictive power of MSI-H in LNM, the sample size is relatively small. Further large scale studies are required to confirm our observation.

ACKNOWLEDGEMENTS

This study was supported by a faculty research grant from Yonsei University College of Medicine (6-2010-0134).

REFERENCES

1. Kitajima K, Fujimori T, Fujii S, Takeda J, Ohkura Y, Kawamata H, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma:
a Japanese collaborative study. J Gastroenterol 2004;39:534-43.
2. Tomiagin K, Nakashiyi Y, Nimura S, Yoshimura K, Sakai Y, Shi-
moda T. Predictive histopathologic factors for lymph node metas-
tasis in patients with nonpedunculated submucosal invasive colorectal cancer. Dis Colon Rectum 2005;48:92-100.
3. Yamamoto S, Watanabe M, Hasegawa H, Baba H, Yoshinare K, Shi-
raishi J, et al. The risk of lymph node metastasis in T1 colorectal
carcinoma. Hepatogastroenterology 2004;51:998-1000.
4. Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph
death metastasis in T1 carcinoma of the colon and rectum.
Dis Colon Rectum 2002;45:2006.
5. Minsky BD, Rich T, Recht A, Harvey W, Mies C. Selection crite-
ria for local excision with or without adjuvant radiation therapy
for rectal cancer. Cancer 1989;63:1421-9.
6. Takano S, Kato J, Yamamoto H, Shiode J, Nasu J, Kawamoto H, et al. Identification of risk factors for lymph node metastasis of colorectal cancer. Hepatogastroenterology 2007;54:746-50.
7. Wang H, Wei Z, Fu CG, Zhao RH, Cao FA. Patterns of lymph node metastasis are different in colon and rectal carcinomas. World J Gastroenterol 2010;16:5375-9.
8. Mou S, Soetikno R, Shimoda T, Rouse R, Kaltenbach T. Patholo-
gic predictive factors for lymph node metastasis in submucosal invasive (T1) colorectal cancer: a systematic review and meta-
analysis. Surg Endosc 2013;27:2692-703.
9. Shibata D, Peinado MA, Ionov Y, Malkhosyan S, Peruchon M. Ge-
nomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet 1994;6:273-81.
10. Yamashita K, Dai T, Dai Y, Yamamoto F, Peruchon M. Genetics su-
persed epigenetics in colon cancer phenotype. Cancer Cell 2003;4:121-31.
11. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The signif-
icance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003;3:695-701.
12. Nasu T, Oki Y, Takifjii K, Hotta T, Yokoyama S, Matsuda K, et al. Predicting lymph node metastasis in early colorectal cancer using the CITED1 expression. J Surg Res 2013;185:136-42.
13. Chung DC, Rustgi AK. DNA mismatch repair and cancer. Gastro-
enterology 1995;109:1685-99.
14. Rhyu MS. Molecular mechanisms underlying hereditary nonpol-
yposis colorectal cancer. J Natl Cancer Inst 1996;88:240-51.
15. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in the proximal colon. Science 1993;260:816-9.
16. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. National Cancer Institute Workshop on Micro-
satellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
17. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltonikki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-7.
18. Boland CR, Shin SK, Goel A. Promoter methylation in the genesis of gastrointestinal cancer. Yonsei Med J 2009;50:309-21.
19. Michel S, Benner A, Tariverdian M, Wentzensen N, Hoepler P, Pommereenke T, et al. High density of FOXPF-positive T cells infiltrating colorectal cancers with microsatellite instability. Br J Cancer 2008;99:1867-73.
20. Gafar R, Maestri I, Matteuzzi M, Santini A, Ferretti S, Cavazzini L, et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 2000;89:2025-37.
21. Liang JT, Huang KC, Cheng AL, Jeng YM, Wu MS, Wang SM. Clinicopathological and molecular biological features of colorec-
tal cancer in patients less than 40 years of age. Br J Surg 2003;90:
205-14.
22. Gryfe R, Kim H, Hsiieh ET, Aronson MD, Holowaty EJ, Ball SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
23. Lim SB, Jeong SY, Lee MR, Ku JL, Shin YK, Kim WH, et al. Prognostic significance of microsatellite instability in sporadic colorectal cancer. Int J Colorectal Dis 2004;19:533-7.
24. Malesci A, Laghi L, Bianchi P, Delconte G, Randolph A, Torri V, et al. Reduced likelihood of metastases in patients with microsat-
ellite-unstable colorectal cancer. Clin Cancer Res 2007;13:3831-9.
25. Loukola A, Eklin K, Laiho P, Salovaara R, Kristo P, Järvinen H, et al. Microsatellite marker analysis in screening for hereditary non-
polyposis colorectal cancer (HNPCC). Cancer Res 2001;61:4545-9.
26. Kim H, An JY, Noh SH, Shin SK, Lee YC, Kim H. High micro-
satellite instability predicts good prognosis in intestinal-type gas-
tric cancers. J Gastroenterol Hepatol 2011;26:585-92.
27. Huddy SP, Husband EM, Cook MG, Gibbs NM, Marks CG, Heald RJ. Lymph node metastases in early colorectal cancer. Br J Surg 1993;80:1457-8.
28. Tepper JE, O’Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB 3rd, et al. Impact of number of nodes retrieved on out-
come in patients with rectal cancer. J Clin Oncol 2001;19:157-63.
29. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph
node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007;99:433-41.
30. Le Voyer TE, Sigurdsson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, et al. Colon cancer survival is associated with in-
ncreasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21:2912-9.
31. Ogino S, Nosho K, Iraha N, Shimba K, Baba Y, Kirkner GJ, et al. Negative lymph node count is associated with survival of colorec-
tal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol 2010;105:420-33.
32. Belt EJ, te Velde EA, Krijgsman O, Brosens RP, Tijssen M, van
Essen HF, et al. High lymph node yield is related to microsatellite instability in colon cancer. Ann Surg Oncol 2012;19:1222-30.
33. MacQuarrie E, Armaso T, Gruchy J, Yan S, Drucker A, Huang WY. Microsatellite instability status does not predict total lymph
node or negative lymph node retrieval in stage III colon cancer. Hum Pathol 2012;43:1256-64.
34. Soreide K, Ogino S. Microsatellite instability and retrieval of lymph
nodes in stage III colorectal cancer: harbinger or hermit? Hum Pathol 2012;43:1785-6.